James Surmeier, PhD, is the Nathan Smith Davis Professor and Chair of the Department of Neuroscience at the Feinberg School of Medicine at Northwestern University. He studied mathematics as an undergraduate at the University of Idaho and received his PhD in physiology and biophysics at the University of Washington. He pioneered the use of advanced electrophysiological, optical,, and molecular approaches to unravel the roles of dopamine and acetylcholine in modulating the striatal circuitry implicated in Parkinson’s disease. These studies have yielded fundamental insights into how striatal circuits adapt to the disease and how they contribute to side -effects of symptomatic treatment. In addition, Dr. Surmeier’s group has made a significant contribution to our understanding of how the physiology of dopaminergic neurons leads to the mitochondrial oxidant stress implicated in Parkinson’s disease pathogenesis. These studies have served as a foundation for large-scale clinical trials aimed at slowing Parkinson’s disease progression.
Coordinating Lead PI
D. James Surmeier, PhD
Northwestern University
James Surmeier, PhD, is the Nathan Smith Davis Professor and Chair of the Department of Neuroscience at the Feinberg School of Medicine at Northwestern University. He studied mathematics as an undergraduate at the University of Idaho and received his PhD in physiology and biophysics at the University of Washington. He pioneered the use of advanced electrophysiological, optical,, and molecular approaches to unravel the roles of dopamine and acetylcholine in modulating the striatal circuitry implicated in Parkinson’s disease. These studies have yielded fundamental insights into how striatal circuits adapt to the disease and how they contribute to side -effects of symptomatic treatment. In addition, Dr. Surmeier’s group has made a significant contribution to our understanding of how the physiology of dopaminergic neurons leads to the mitochondrial oxidant stress implicated in Parkinson’s disease pathogenesis. These studies have served as a foundation for large-scale clinical trials aimed at slowing Parkinson’s disease progression.
